Publications by authors named "R McComb"
Sialadenoma papilliferum is a tumor characterized by surface papillary projections and glandular/microcystic proliferation at the lesion base. Cases in which surface involvement is absent have been termed "sialadenoma papilliferum-like intraductal papillary tumor." Similar tumors that are present in the mandible have been termed "tubulopapillary hidradenoma-like tumor of the mandible.
View Article and Find Full Text PDFAmyloid-beta related angiitis (ABRA) is a rare central nervous system inflammatory and vasculitic process. It is seen in patients with cerebral amyloid angiopathy (CAA) and thought to be mediated by an autoimmune reaction against cerebrovascular β-amyloid. We describe the case of a patient with ABRA with clinical information and brain imaging over a 10-year period.
View Article and Find Full Text PDFArticle Synopsis
- The ICONIC trial examined the safety and effectiveness of the investigational drug vopratelimab, both alone and with nivolumab, in patients with advanced solid tumors.
- A total of 201 patients were enrolled, with the study determining a safe dosing schedule and finding that vopratelimab was generally well tolerated but had modest response rates.
- A specific biomarker, ICOS-high CD4 T cells, was linked to better clinical outcomes, indicating that some patients may respond more positively to the treatment, prompting further investigation in upcoming trials.
Article Synopsis
- Anthrax is a serious disease that can almost always be deadly because of a harmful toxin it produces.
- Researchers studied a drug called amodiaquine (AQ), which can help stop this toxin from harming the body.
- Tests on mice, rabbits, and humans showed that AQ significantly increased survival rates in infected animals and seemed safe for people when used correctly.
Introduction: Glioblastoma (GBM) is heterogeneous and underlying genomic profiles influence evolution, resistance, and therapeutic responses. While extensive knowledge regarding genomic profiling of primary GBM exists, there remains a lack of understanding of genomic differences in recurrent GBM.
Methods: We used the FoundationOne® comprehensive genomic profiling assay (CGP) to analyze ten matched primary and recurrent GBM.